



# Journal of Applied Nonlinear Dynamics

Miguel A. F. Sanjuan (editor), Albert C.J. Luo (editor)

ISSN:2164-6457 (print)

ISSN:2164-6473 (online)

## Effect of Medication in a Glucose-Insulin Mathematical Model

*Journal of Applied Nonlinear Dynamics* 13(4) (2024) 795-803 | DOI:10.5890/JAND.2024.12.012

Evandro G. Seifert<sup>1</sup>, Jos'e Trobia<sup>2</sup>, F'atima E. Cruziniani<sup>1,2</sup>, Diogo L. M. de Souza<sup>1</sup>, Elaheh Sayari<sup>1</sup>, Enrique C. Gabrick<sup>1</sup>, Kelly C. Iarosz<sup>1,3,4</sup>, Jos'e D. Szezech Jr<sup>1,2</sup>, Iber^e L. Caldas<sup>4</sup>, Antonio M. Batista<sup>1,2,4</sup>

<sup>1</sup> Graduate Program in Sciences, State University of Ponta Grossa, 84030-900, Ponta Grossa, PR, Brazil

<sup>2</sup> Department of Mathematics and Statistics, State University of Ponta Grossa, 84030-900, Ponta Grossa, PR, Brazil

<sup>3</sup> University Center UNIFATEB, 84266-010, Tel^emaco Borba, PR, Brazil

[Aims and Scope](#)

[Paper Submission](#)

[Editorial Board](#)

[Access Full Text](#)

[Article Offprint Order Form](#)

[Peer-Review](#)

**Policies**

**Bylaws**

**for**

**Editorial**

**Policies**

**Open**

**Access**

**Options**

**Copyright**

**Form**

**Manuscript**

**Template**

**Ethics &**

**Malpractice**

**Statement**

<sup>4</sup> Physics Institute, University of São Paulo, 05508-900, São Paulo, SP, Brazil

## **Download Full Text PDF**

### **Abstract**

Insulin is a hormone that plays a crucial role in regulating the blood glucose. It is secreted by the beta cells of the pancreas. A chronic disease, known as diabetes, occurs when there is no effective use or no enough secretion of insulin. The treatment, such as insulin injections and medicines, depends on the type of diabetes.

Mathematical models have been proposed to understand the dynamics of the glucose-insulin regulatory system in different conditions. In this work, we investigate a model that describes the dynamics of the glucose and insulin concentrations with beta cells. We introduce the effect of medication in a glucose-insulin model. It is analysed a treatment with continuous medication and another with discontinuity in the drug use. We identify parameter values related to medicines that maintain the blood glucose concentration in a normal level.

### **Acknowledgments**

This work was possible by partial financial support from the following Brazilian government agencies: Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) (2018/03211-6, 2022/13761-9), Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) (311168/2020-5, 350073/2022-8), CAPES, and São Paulo Research Foundation (FAPESP 2018/03211-6, 2022/13761-9). We would like to thank 105 Group Science (www.105groupscience.com).

### **References**

- [1] Petersen, M.C. and Shulman, G.I. (2018), Mechanisms of insulin action and insulin resistance, *Physiological Reviews*, 98, 2133-2223.
- [2] Henquin, J.C., Ravier, M.A., Nenquin, M., Jonas, J.C., and Gilon, P. (2003), Hierarchy of the beta-cell signals

controlling insulin secretion, *European Journal of Clinical* 33, 742-750.

- [3] Tirone, T.A. and Brunicardi, F.C. (2001), Overview of glucose homeostasis, *World Journal of Surgery*, 25, 461-467.
- [4] G\u00fcl\u00fcemes, M., Rahman, S.A., and Hussain, K. (2016), What is the normal range of blood glucose?, *Archives of Disease in Childhood*, 101, 1-4.
- [5] Hu, R., Xia, C.-Q., Butfiloski, E., and Clare-Salzler, M. (2007), High glucose on cytokine production by human peripheral blood mononuclear cells and type I interferon signaling in monocytes: Implications for the role of hyperglycemia in the diabetes inflammatory response, *Journal of Clinical Investigation*, 117, 1307-1315.
- [6] Cryer, P.E., Davis, S.N., and Shamoon, H. (2003), Hypoglycemia in type 1 diabetes: Mechanisms, diagnosis, and treatment, *Diabetes Care*, 26, 1902-1912.
- [7] Zammitt, N.N. and Frier, B.M. (2005), Hypoglycemia in type 2 diabetes: Pathophysiology, frequency, and effects of different treatment modalities, *Diabetes Care*, 28, 2948-2961.
- [8] Zimmet, P.Z., Magliano, D.J., Herman, W.H., and Shaw, J. (2012), Diabetes: a 21st century challenge, *Lancet Diabetes & Endocrinology*, 10, 56-64.
- [9] DiMeglio, L.A., Evans-Molina, C., and Oram, R.A. (2018), Type 1 diabetes mellitus, *The Lancet*, 391, 2449-2462.
- [10] Chatterjee, S., Khunti, K., and Davies, M.J. (2017), Type 2 diabetes, *Lancet*, 389, 2239-2251.
- [11] Nathan, D.M. (2015), Diabetes: Advances in diagnosis and management, *JAMA*, 314, 1052-1062.
- [12] Berget, C., Messer, L.H., and Forlenza, G.P. (2019), A clinical review of continuous subcutaneous insulin infusion therapy for the management of diabetes mellitus, *Diabetes Spectrum*, 32, 10-15.
- [13] Bailey, C.J. (2017), Metformin: Historical overview, *Diabetes Therapy*, 1566-1576.
- [14] Cusi, K. and DeFronzo, R.A. (1998), Metformin: A review of its metabolic effects, *Diabetes Reviews*, 6, 89-131.
- [15] Greville, G.D. (1943), The intravenous glucose tolerance test, *Biochemical Journal*, 37, 17-24.
- [16] Bolie, V.W. (1961), Coefficients of normal blood glucose tolerance, *Journal Applied Physiology*, 16, 783-788.
- [17] Bajaj, J.S., Rao, G.S., Rao, J.S., and Khardori, R. (1987), A mathematical model for insulin kinetics and its application to proteinuria (malnutrition-related) diabetes mellitus (PDDM), *Journal of Biological Chemistry*, 262, 491-503.
- [18] Kartono, A., Malik, S., Syafutra, H., Wahyudi, S.T., and Satrio, H. (2019), Pharmacokinetics simulation of metformin in type 2 diabetes mellitus, *Journal of Physics: Conference Series*, 1171, 012001.
- [19] Katz, A., Nambi, S.S., Mather, K., Baron, A.D., Follman, D., and Quon, M.J. (2000), Quantitative insulin sensitivity index: A simple, accurate method for assessing insulin sensitivity in humans, *The Journal of Clinical Endocrinology & Metabolism*, 82, 2524-2532.
- [20] Trobia, J., de Souza, S.L.T., dos Santos, M.A., Szezech Jr, A.M., Borges, R.R., Pereira, L.S., Protachevicz, P.R., Caldarella, K.C. (2022), On the dynamical behaviour of a glucose-insulin model, *Chaos, Solitons & Fractals*, 155, 111753.
- [21] Shabestari, P.S., Panahi, S., Hatef, B., Jafari, S., and Spricci, A. (2021), A new chaotic model for glucose-insulin regulatory system, *Solitons & Fractals*, 112, 44-51.

- [22] Scheen, A.J. (1996), Clinical pharmacokinetics of metfo  
Pharmacokinetics, 30, 359- 371.
- [23] Holling, C.S. (1959), Some characteristics of simple typ  
and parasitism, The Canadian Entomologist, 91, 385-3
- [24] Rao, G.S., Bajaj, J.S., and Rao, J.S. (1990), A mathematic  
insulin kinetics. II. Extension of the model to include re  
glucose administration and application to insulin-dep  
mellitus (IDDM), Journal of Theoretical Biology, 142, 4
- [25] Foster, R.H. and Plosker, G.L. (2000), Glipizide. A review  
pharmacoeconomic implications of the extended-rele  
in type 2 diabetes mellitus, Pharmacoeconomics, 18, 2
- [26] Ackerman, E., Gatewood, L.C., Rosevear, J.W., and McG  
(1964), A mathematical model of the glucose-toleranc  
Medicine & Biology, 9, 203-213.
- [27] Ackerman, E., Gatewood, L.C., Rosevear, J.W., and Mol  
Model studies of blood-glucose regulation, The Bullet  
Mathematical Biophysics, 27, 21-37.
- [28] Pinho, S.T.R, Freedman, H.I., and Nani, F. (2002), A chem  
model for the treatment of cancer with metastasis, Ma  
Computer Modelling, 36, 773-803.
- [29] Pinho, S.T.R., Rodrigues, D.S., and Mancera, P.F.A. (201  
mathematical model of chemotherapy response to tur  
Canadian Applied Mathematics Quarterly, 4, 369-384.